Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Gilead Sciences...

    Gilead Sciences chooses Chengdu Hi-tech Zone for Western China Operation Center project

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-12T09:10:21+05:30  |  Updated On 2021-08-16T13:13:48+05:30

    Established in 1987 and headquartered in California, Gilead Sciences is one of the top 10 pharmaceutical companies in the world. As a pioneer in producing drugs for AIDS and hepatic diseases, its business income amounted to USD 22.1 billion in 2018, ranking the 455th on the Fortune Global 500 list.


    New Delhi: Chengdu Hi-tech Zone and Gilead Sciences inked a strategic cooperation agreement on the Gilead Sciences Western China Operation Center project, which marked the official registration of its western China operation center in Chengdu Hi-tech Zone.


    Established in 1987 and headquartered in California, Gilead Sciences is one of the top 10 pharmaceutical companies in the world. As a pioneer in producing drugs for AIDS and hepatic diseases, its business income amounted to USD 22.1 billion in 2018, ranking the 455th on the Fortune Global 500 list.


    Read Also: Top China medical device manufacturer risks getting too pricey: Report


    It was introduced by Luo Yongqing, Global Vice President of Gilead Sciences and General Manager of Gilead Sciences (China), that the establishment was to take Sichuan and Chengdu Hi-tech Zone as one of its important strategic bases in China. Going forward, the center will be mainly engaged in the operation and management of Gilead Sciences' business in western China, which will be of great significance to effectively promoting the development of the bio engineering and pharmaceutical industry in Chengdu and Sichuan and even the central and western China.


    As an important node city in the junction of "Belt & Road" and Yangtze River Economic Belt, Chengdu has already opened 112 international (regional) flights. Chengdu is the only city in central and western China that owns two airports. The annual passenger throughput of Chengdu Shuangliu International Airport reaches 50 million. Chengdu has become a favored destination for foreign investment owing to its continuously-optimized international business environment in recent years. So far, 288 of Fortune Global 500 have set up their offices in Chengdu, mainly from 22 regions such as Europe, US, Japan, and South Korea.


    As Chengdu's main field of bioengineering and pharmaceutical industry, Chengdu Hi-tech Zone has been striving to set up modern biological industrial system with international competitiveness in recent years. Chengdu Tianfu International Bio-town which was completed in 2016 has attracted 127 projects up to now with an overall investment agreement valued at more than RMB 100 billion. Furthermore, it has introduced five Nobel Prize-winning teams. Chengdu Hi-tech Zone jumped to the 6th place on the overall competitiveness ranking among 171 biomedical industrial parks in 2018 selected by the National Center for Biotechnology Information of the Ministry of Science and Technology of the People's Republic of China.

    AIDS Chengdu Hi-tech Zone Gilead Sciences hepatic diseases Luo Yongqing pharma pharma company pharma news pharmaceutical companies Sichuan Western China Operation 

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      3.36% of about 82,600 drugs samples found to be substandard

      3.36% of about 82,600 drugs samples found to be substandard

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Apollo medical centre in Oman granted hospital status

      Apollo medical centre in Oman granted hospital status

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs 9700 crore

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs...

      Calcutta HC sets aside Centers decision for strategic sale of Bengal Chemicals

      Calcutta HC sets aside Center's decision for strategic sale of Bengal Chemicals

      Aurobindo Pharma receives USFDA approval to manufacture ADHD drug

      Aurobindo Pharma receives USFDA approval to manufacture ADHD drug

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society petition

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society...

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 27 May 2022 6:45 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X